Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dianna Tyznar
Institution:
Memorial Sloan Kettering Cancer Center
Observed institution:
Memorial Sloan Kettering Cancer Center
OpenAlex ID:
A5093396596
A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation
2023
·
Lindsey E. Roeker
, Andrew D. Zelenetz
, et al.
·
Blood
·
4
PDF
Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
2024
·
Lindsey Roeker
, Anthony R. Mato
, et al.
·
Blood
·
2
PDF
Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia
2025
·
Meghan Thompson
, Anthony Mato
, et al.
·
Blood
·
1
Show more works
View as search
Works count:
3
Citation count:
7
H-index:
2
I10-index:
Year
Topic
Type
